ArticlePharmaceutics2021
Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide.
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation.Molecular cancer · 2026Review
- Tumor-Targeted Radioiodinated Glyconanoparticles for Doxorubicin Delivery and Auger-Chemotherapy in Triple-Negative Breast Cancer.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Clinical Evidence of Combining Radiopharmaceutical Therapy With Immune Checkpoint Inhibitors.Applied radiation oncology · 2025Article
- The effects of cell displacement on DNA damages in targeted radiation therapy using Geant4-DNA.Scientific reports · 2024Article
- Enhancement of gold-curcumin nanoparticle mediated radiation response for improved therapy in cervical cancer: a computational approach and predictive pathway analysis.Discover nano · 2024Article
- Immunological effects of radiopharmaceutical therapy.Frontiers in nuclear medicine · 2024Review
- Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Review
- PET Imaging of the Neurotensin Targeting Peptide NOTA-NT-20.3 Using Cobalt-55, Copper-64 and Gallium-68.Pharmaceutics · 2022Article
- Dosimetry in Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- The influence of degree of labelling upon cellular internalisation of antibody-cell penetrating peptide conjugates.RSC advances · 2022Article
- A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT).Pharmaceutics · 2022Review
- Relevance of Palladium to Radiopharmaceutical Development Considering Enhanced Coordination Properties of TE1PA.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Searching for a Paradigm Shift in Auger-Electron Cancer Therapy with Tumor-Specific Radiopeptides Targeting the Mitochondria and/or the Cell Nucleus.International journal of molecular sciences · 2022Article
- Relationship of In Vitro Toxicity of Technetium-99m to Subcellular Localisation and Absorbed Dose.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Auger electron emitters (AEEs) are attractive tools in targeted radionuclide therapy to specifically irradiate tumour cells while sparing healthy tissues. However, because of their short range, AEEs need to be brought close to sensitive targets, particularly nuclear DNA, and to a lower extent, cell membrane. Therefore, radioimmunoconjugates (RIC) have been developed for specific tumour cell targeting and transportation to the nucleus. Herein, we assessed, in A-431
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.